121,959 Shares in Pfizer Inc. (NYSE:PFE) Bought by Inlight Wealth Management LLC

Inlight Wealth Management LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 121,959 shares of the biopharmaceutical company's stock, valued at approximately $3,236,000. Pfizer makes up 1.0% of Inlight Wealth Management LLC's holdings, making the stock its 20th largest position.

Several other large investors have also recently bought and sold shares of PFE. Nordea Investment Management AB boosted its position in Pfizer by 36.1% during the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock worth $108,002,000 after purchasing an additional 1,080,822 shares in the last quarter. Parsons Capital Management Inc. RI boosted its position in shares of Pfizer by 118.7% in the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock worth $7,820,000 after buying an additional 159,984 shares in the last quarter. Copley Financial Group Inc. acquired a new stake in Pfizer in the 3rd quarter valued at about $577,000. Mcdonald Partners LLC increased its holdings in Pfizer by 9.9% during the 4th quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock valued at $2,926,000 after acquiring an additional 9,963 shares in the last quarter. Finally, Merit Financial Group LLC raised its position in Pfizer by 60.8% during the fourth quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company's stock worth $3,395,000 after acquiring an additional 48,397 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Remove Ads

Pfizer Trading Up 0.9 %

Shares of NYSE:PFE traded up $0.19 during trading on Monday, reaching $22.10. 61,845,565 shares of the stock were exchanged, compared to its average volume of 40,318,640. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The firm's 50-day moving average price is $25.25 and its 200 day moving average price is $26.38. The firm has a market cap of $125.34 billion, a price-to-earnings ratio of 15.67, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the previous year, the firm posted $0.10 earnings per share. The firm's quarterly revenue was up 24.7% on a year-over-year basis. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on PFE. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. UBS Group lowered their target price on Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a report on Tuesday, April 8th. Citigroup reissued a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $31.07.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock bought 19,457 shares of the firm's stock in a transaction dated Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is owned by company insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.